Edesa Biotech, Inc. (EDSA)

4.4800 -0.0600 (-1.32%) At close: 04:00PM EDT

Edesa Biotech, Inc.

100 Spy Court
Markham, ON L3R 5H6
Canada
289 800 9600
https://www.edesabiotech.com

Sector(s): Healthcare
Industry: Biotechnology
Full Time Employees: 16

Key Executives

Name	Title	Pay	Exercised	Year Born
Dr. Pardeep Nijhawan FRCPC, M.D.	CEO, Company Secretary & Director	475.33k	N/A	1971
Dr. Michael J. Brooks M.B.A., Ph.D.	President	439.27k	N/A	1978
Mr. Stephen L. Lemieux BA, CPA, CA, CPA, MMPA	Chief Financial Officer	402.86k	N/A	1977

Amounts are as of December 31, 2023 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Edesa Biotech, Inc., a clinical-stage biopharmaceutical company, engages in the research and development, manufacture, and commercialization of pharmaceutical products for inflammatory and immune-related diseases. Its lead product candidates are EB05, a monoclonal antibody, which is in Phase 3 clinical study for the treatment of acute respiratory distress syndrome in Covid-19 patients; and EB01, a topical vanishing cream containing non-steroidal anti-inflammatory compound that has completed Phase 2b clinical study to treat chronic allergic contact dermatitis. The company also develops EB02, an extension of secretory phospholipase 2 anti-inflammatory cream for treating erythema, swelling, and exudation associated with hemorrhoids disease; and EB06, an anti- chemokine ligand 10 (CXCL10) monoclonal antibody in vitiligo. It has a collaboration agreement with NovImmune SA to develop monoclonal antibodies targeting products containing toll-like receptor 4 and CXCL10 for therapeutic, prophylactic, and diagnostic applications in humans and animals; and Yissum Research Development Company for the development of products for therapeutic, prophylactic, and diagnostic uses in topical dermal and anorectal applications, as well as for the use in dermatologic and gastrointestinal conditions. The company was founded in 2015 and is headquartered in Markham, Canada.

Corporate Governance

Edesa Biotech, Inc.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.